Article Contents ::
- 1 The Brand Name DEPOXIT Has Generic Salt :: Fluoxetine
- 2 DEPOXIT Is From Company Olcare Priced :: Rs. 18.5
- 3 DEPOXIT have Fluoxetine is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name DEPOXIT Has Generic Salt :: Fluoxetine
DEPOXIT Is From Company Olcare Priced :: Rs. 18.5
DEPOXIT have Fluoxetine is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Fluoxetine | CAP | Rs. 18.5 | 10 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
| DEPOXIT | Olcare | 20 MG | 10 | Rs. 18.5 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Olcare :: DEPOXIT | Fluoxetine | #N/A | #N/A |
Indications for Drugs ::
Panic disorder, Obsessive compulsive disorder, Trichotillomania, Premenstrual dysphoric disorder, Major depression, Post-traumatic stress disorder, Bulimia nervosa, Body dysmorphic disorder, Binge eating disorder
Drug Dose ::
Adults only; without regard to meals. Depression: Adults and elderly: A dose of 20 mg/day is recommended. Bulimia nervosa: Adults and elderly: A dose of 60 mg/day is recommended. Obsessive compulsive disorder: The recommended starting dose is 20mg/day which can be gradually increased to 60 mg/day. Child: 7-18 yr: Initially, 10 mg daily; may increase to 20 mg daily after 2 wk in adolescents and higher-wt children. Usual range: 10-60 mg daily. In premenstrual syndrome: usual dose is 20 mg/day or as directed by the physician.
Contraindication ::
Severe renal or hepatic failure; hypersensitivity; lactation; concomitant MAOIs or within 2 wk of MAOI withdrawal.
Drug Precautions ::
Unstable epilepsy, liver and renal impairment, cardiac disease, diabetes, electroconvulsive therapy, bleeding disorders, closed-angle glaucoma; pregnancy. May impair performace of skilled tasks; withdraw gradually. Close monitoring of clinical worsening and behavioural changes during the 1st few mth of treatment or when there are dose changes.
Drug Side Effects ::
Nervousness, insomnia, anxiety, headache, tremor, drowsiness, dry mouth, nausea, vomiting, sweating, diarrhoea. Seizures, mania, hypomania or mixed manic states reported. Hyponatraemia; elevation of hepatic enzymes. Potentially Fatal: Rarely, systemic events possibly related to vasculitis have been reported in patients with rash but may be serious involving lungs, kidney and liver.
Pregnancy category ::
3
Drug Mode of Action ::
Fluoxetine is a potent and highly selective inhibitor of serotonin (5-HT) re-uptake. No affinity for adrenoceptors or histamine, GABA-B, or muscarinic receptors.
Drug Interactions ::
May cause transient shift in plasma conc of tightly protein bound drugs e.g. warfarin and digoxin, resulting in adverse effects. T1/2 of diazepam is prolonged. Avoid concurrent use with clopidogrel. Potentially Fatal: Serious reactions when combined with MAOIs; at least 14 days should elapse after MAOIs withdrawal before starting fluoxetine treatment or at least 5 wk should elapse after fluoxetine treatment before starting MAOIs therapy. Two-fold increase in plasma levels of other antidepressants when combined with fluoxetine. Monitor lithium levels when combined.
